MedPath

A study to compare two different kind of chemotherapy in mouth cancer

Not Applicable
Conditions
Health Condition 1: null- Patients who have unresectable locally advanced head and neck cancer
Registration Number
CTRI/2016/04/006804
Lead Sponsor
Tata Memorial centre
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
492
Inclusion Criteria

1.Histologically or cytologically confirmed squamous cell carcinoma of age more than 18 years;

2.Performance status <= 2 on the ECOG performance scale.

3.There should not be any prior history of any chemotherapy.

4.There should be at least one lesion that is measurable either unidimensionally or bidimensionally.

5.Tumour has to considered technically unresectable by a multidisciplinary team.

6.Estimated life expectancy of at least 12-weeks.

7.Adequate organ and immune system function as indicated by the following laboratory values, obtained <= 3 weeks prior to dosing:

SystemLab value

Hematologic

ANC>= 1.5 Ã? 109 /L

Hb>= 8.0 g/dL

Platelets>= 100 Ã? 109 /L

Renal

Sr. Creatinine<= 2.0 mg/dL

Hepatic

Total Bilirubin<= ULN

AST <= 3 Ã? ULN

ALT<= 3 Ã? ULN

Alkaline Phosphatase<= 5 Ã? ULN

8.Women of childbearing potential must be willing to consent to using effective contraception (eg, hormonal contraceptives, bilateral tubal ligation, barrier with spermicide, intrauterine device) while on treatment and for at least 3 months thereafter. A man who is the partner of a woman of childbearing potential must be willing to consent to using effective contraception (eg, vasectomy or barrier with spermicide) while on treatment and for 3 months thereafter.

9.Willing and able to comply with all study requirements, including treatment, able to be followed up at regular intervals.

10. Signed, written informed consent

Exclusion Criteria

1.Clinical or radiologic evidence of metastatic disease.

2.Any significant active infection, including chronic active hepatitis B, active hepatitis C, HIV infection with AIDS or immunodeficiency syndromes.

3.Serious uncontrolled medical illness (e.g. uncontrolled diabetes mellitus, uncontrolled hypertension, severe infectionor untreated psychiatric conditions) that might limit the ability of the patient to comply with the protocol.

4.Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule, including alcohol dependence or drug abuse.

5.Pregnancy, lactation, or inadequate contraception. Women must be post menopausal, infertile, or willing to use a reliable means of contraception. Women of childbearing potential must have a negative pregnancy test done within 7 days prior to registration. Men must have been surgically sterilised or be willing to use a (double if required) barrier method of contraception

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
overall survivalTimepoint: at two year
Secondary Outcome Measures
NameTimeMethod
Progression Free Survival and Response rateTimepoint: Progression free survival-at one year <br/ ><br>Response rate-at two months
© Copyright 2025. All Rights Reserved by MedPath